An interventional study of Stereotactic Radiosurgery in Brain Neoplasms, Adult, Malignant, sponsored by University of Texas Southwestern Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,447 studies in Brain Neoplasms with a site in United States — 233 open to participants now, 355 under way, 18 of them phase 3. Brain Neoplasms · United States.
Among the 1,447 studies in Brain Neoplasms with a site in United States, this one is the 168th largest by enrollment of the 1,192 interventional ones that give a count, is one of 58 that started in 2015, is one of 226 with no phase, reaches primary completion later than 18 of the 353 other live ones, and was the 876th registered.
2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.
Browse Brain Neoplasms studies →233 of the 1,447 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Brian J.Gill · Sites in United States
Ages 22–65
Stanford University · Sites in United States
Ages 6 mo–25 yrs
University of California, San Francisco · Sites in United States
Ages 18+
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
University of Florida · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,447 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 554 · Phase 2 522 · Phase 3 72 · Phase 4 18
First in 1979; this study’s year is marked. 58 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 40 across 1,838 interventional studies indexed under Brain Neoplasms.
Median enrollment 30 across the 1,192 interventional studies, 76 across the 191 observational. Of the 994 that completed or were terminated, 355 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
221 of 1,447 have an industry lead sponsor. The 10 most frequent:
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
University of Texas Southwestern Medical Center has 8 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
140 of the studies in Brain Neoplasms with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT03741673Phase 3M.D. Anderson Cancer CenterPre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases | 2027-01-31 |
| NCT05438212Phase 3NRG OncologyComparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases | 2027-03-16 |
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT00950001Phase 3M.D. Anderson Cancer CenterStereotactic Radiosurgery Compared to Observation in Treating Patients With Brain Metastases | 2027-04-30 |
Add all 140 to your calendar (.ics) → With an account.
Among the 1,447 studies in Brain Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
SRS dose escalation for brain metastases in radiation-naïve patients will establish true tolerable doses, which may exceed the current standard doses. This may lead to an improvement in local control, patient survival, and/or quality-of life.
Recently, several large randomized studies have shown that in patients with limited brain metastases, whole brain radiation can be safely deferred when treated with SRS and close surveillance. In light of this, most of such patients are now treated with SRS alone without WBRT. However, the SRS doses set by Radiation Therapy Oncology Group (RTOG) 90-05 continue to be applied to patients without previous cranial irradiation.
The potential insufficiency of current SRS dose for long-term tumor control is of pressing concern. The advances chemotherapy has led to an improvement in overall survival in many patients with metastatic cancer, including malignancies often associated with brain metastases, such as lung (40-50%) and breast (15%). As these patients survive longer, more patients may develop brain metastases and the current dose of SRS may not be adequate to control the brain metastases for the duration of their survival. In fact, there is evidence that the control rate declines with time after SRS, and after 3 years, the local control rate may be only about 60%. In the case of brain metastases from relatively radio-resistant melanoma, the reported 12-months local control rates for SRS range from 52% to 75%. More potent SRS doses could lead to improved long-term control of brain metastases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Previous treatment with surgery, radiation, chemotherapy, immunotherapy or any targeted agents are allowed provided that:
All men, as well as women of must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
Exclusion Criteria
Patients with .
NOTE: For the purposes of exclusion, LMD is a clinical diagnosis, defined as positive CSF cytology and/or equivocal radiologic or clinical evidence of leptomeningeal involvement. Patients with leptomeningeal symptoms in the setting of leptomeningeal enhancement by imaging (MRI) would be considered to have LMD even in the absence of positive CSF cytology, unless a parenchymal lesion can adequately explain the neurologic symptoms and/or signs. In contrast, an asymptomatic or minimally symptomatic patient with mild or nonspecific leptomeningeal enhancement (MRI) would not be considered to have LMD. In that patient, CSF sampling is not required to formally exclude LMD, but can be performed at the investigator's discretion based on level of clinical suspicion.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Radiation, Stereotactic Radiosurgery Dose-Escalation
Radiation: Stereotactic Radiosurgery
Radiation, Stereotactic Radiosurgery Size \<= 1cm: 24 Gray (Gy); + 3 Gy incremental escalation up to 30 Gy \>1-2cm: 21 Gy; + 3 Gy incremental escalation up to 27 Gy \>2-3cm: 18 Gy; + 3 Gy incremental escalation up to 24 Gy
Also known as: SRS
Maximal Tolerated Doses
The maximal tolerated doses for single-fraction stereotactic radiosurgery, within 90 days from the date of procedure, in patients with brain metastases who have not undergone prior brain irradiation was determined according to the following conditions: if zero or one out of the first seven, two or fewer out of the first nine, three or fewer out of the first twelve, or four or fewer out of the first fifteen of patients within 3-month follow-up experience a dose-limiting toxicity (DLT) as defined in the study protocol, then the dose was escalated to the next dose level according to principal investigator discretion. If three or more of the first nine patients, four or more of the first twelve, or five or more of the first fifteen patients experienced a DLT, then the maximum tolerated dose (MTD) was considered to have been exceeded. Each cohort had 3 maximum dose levels that could be met by reaching the dose escalation conditions.
Time frame: 90 days
Overall Survival
To evaluate the overall survival (OS), which is defined as the time between date of SRS and the date of death due to any cause.
Time frame: 3 years
Time to Progression
To evaluate time to progression (TTP), which is defined as the time between date of SRS and date of documented progression. Specific TTP will be determined for the target lesion, non-target lesions, and elsewhere in brain.
Time frame: 3 years
Local Progression Rate
To evaluate the local progression rate of the target lesion. Local progression will be defined by MRI (with or without contrast)/CT (with contrast) imaging according to the modified RECIST 1.1 criteria. Suspected radiation necrosis and/or pseudoprogression will be similarly evaluated
Time frame: 3 years
Response Rate
To evaluate the response rate, consisting of complete response (CR) and partial response according to the modified RECIST 1.1.
Time frame: 3 years
| Milestone | Cohort 1 Dose Level 1 | Cohort 1 Dose Level 2 | Cohort 1 Dose Level 3 | Cohort 2 Dose Level 1 | Cohort 2 Dose Level 2 | Cohort 2 Dose Level 3 | Cohort 3 Dose Level 1 | Cohort 3 Dose Level 2 | Cohort 4 Dose Level 1 |
|---|---|---|---|---|---|---|---|---|---|
| Started | 16 | 12 | 8 | 15 | 14 | 9 | 17 | 7 | 7 |
| Completed treatment | 13 | 12 | 7 | 14 | 14 | 9 | 13 | 7 | 7 |
| Completed | 6 | 4 | 1 | 6 | 6 | 3 | 6 | 0 | 2 |
| Not completed | 10 | 8 | 7 | 9 | 8 | 6 | 11 | 7 | 5 |
| Withdrew: Death | 7 | 3 | 3 | 8 | 6 | 2 | 6 | 4 | 5 |
| Withdrew: Screen failure | 3 | 1 | 1 | 1 | 0 | 0 | 4 | 0 | 0 |
| Withdrew: Physician decision | 0 | 3 | 1 | 0 | 2 | 3 | 1 | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Active follow up | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
The maximal tolerated doses for single-fraction stereotactic radiosurgery, within 90 days from the date of procedure, in patients with brain metastases who have not undergone prior brain irradiation was determined according to the following conditions: if zero or one out of the first seven, two or fewer out of the first nine, three or fewer out of the first twelve, or four or fewer out of the first fifteen of patients within 3-month follow-up experience a dose-limiting toxicity (DLT) as defined in the study protocol, then the dose was escalated to the next dose level according to principal investigator discretion. If three or more of the first nine patients, four or more of the first twelve, or five or more of the first fifteen patients experienced a DLT, then the maximum tolerated dose (MTD) was considered to have been exceeded. Each cohort had 3 maximum dose levels that could be met by reaching the dose escalation conditions.
| gray | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Maximal Tolerated Doses | 30 | 27 | 21 | 15 |
To evaluate the overall survival (OS), which is defined as the time between date of SRS and the date of death due to any cause.
Results for this outcome have not been posted.
To evaluate time to progression (TTP), which is defined as the time between date of SRS and date of documented progression. Specific TTP will be determined for the target lesion, non-target lesions, and elsewhere in brain.
Results for this outcome have not been posted.
To evaluate the local progression rate of the target lesion. Local progression will be defined by MRI (with or without contrast)/CT (with contrast) imaging according to the modified RECIST 1.1 criteria. Suspected radiation necrosis and/or pseudoprogression will be similarly evaluated
Results for this outcome have not been posted.
To evaluate the response rate, consisting of complete response (CR) and partial response according to the modified RECIST 1.1.
Results for this outcome have not been posted.
Collected over Adverse events were collected at baseline pre-treatment and every 3 months after the completion of treatment, up to 1 year.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 Dose Level 1 | 7/13 (53.8%) | 2/13 (15.4%) | 13/13 (100%) |
| Cohort 1 Dose Level 2 | 3/12 (25%) | 6/12 (50%) | 12/12 (100%) |
| Cohort 1 Dose Level 3 | 3/7 (42.9%) | 1/7 (14.3%) | 7/7 (100%) |
| Cohort 2 Dose Level 1 | 8/14 (57.1%) | 1/14 (7.1%) | 13/14 (92.9%) |
| Cohort 2 Dose Level 2 | 6/14 (42.9%) | 7/14 (50%) | 14/14 (100%) |
| Cohort 2 Dose Level 3 | 2/9 (22.2%) | 6/9 (66.7%) | 9/9 (100%) |
| Cohort 3 Dose Level 1 | 8/13 (61.5%) | 6/13 (46.2%) | 12/13 (92.3%) |
| Cohort 3 Dose Level 2 | 5/7 (71.4%) | 3/7 (42.9%) | 7/7 (100%) |
| Cohort 4 Dose Level 1 | 5/7 (71.4%) | 4/7 (57.1%) | 5/7 (71.4%) |
| Event | Cohort 1 Dose Level 1 | Cohort 1 Dose Level 2 | Cohort 1 Dose Level 3 | Cohort 2 Dose Level 1 | Cohort 2 Dose Level 2 | Cohort 2 Dose Level 3 | Cohort 3 Dose Level 1 | Cohort 3 Dose Level 2 | Cohort 4 Dose Level 1 |
|---|---|---|---|---|---|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 0/13 | 0/12 | 0/7 | 0/14 | 0/14 | 2/9 | 0/13 | 1/7 | 0/7 |
| SepsisInfections and infestations | 0/13 | 2/12 | 1/7 | 0/14 | 0/14 | 2/9 | 0/13 | 1/7 | 0/7 |
| Intracranial hemorrhageNervous system disorders | 0/13 | 2/12 | 0/7 | 0/14 | 0/14 | 1/9 | 0/13 | 0/7 | 0/7 |
| DysphagiaGastrointestinal disorders | 0/13 | 0/12 | 0/7 | 0/14 | 0/14 | 0/9 | 2/13 | 0/7 | 0/7 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/13 | 0/12 | 0/7 | 0/14 | 1/14 | 0/9 | 2/13 | 0/7 | 1/7 |
| Lung infectionInfections and infestations | 1/13 | 1/12 | 0/7 | 0/14 | 1/14 | 1/9 | 2/13 | 0/7 | 0/7 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/13 | 0/12 | 1/7 | 0/14 | 0/14 | 1/9 | 0/13 | 0/7 | 0/7 |
| Abdominal painGastrointestinal disorders | 0/13 | 0/12 | 1/7 | 0/14 | 2/14 | 0/9 | 0/13 | 0/7 | 1/7 |
| Acute kidney injuryRenal and urinary disorders | 0/13 | 0/12 | 0/7 | 0/14 | 0/14 | 1/9 | 0/13 | 1/7 | 0/7 |
| AnorexiaMetabolism and nutrition disorders | 0/13 | 0/12 | 0/7 | 0/14 | 0/14 | 0/9 | 0/13 | 0/7 | 1/7 |
| Event | Cohort 1 Dose Level 1 | Cohort 1 Dose Level 2 | Cohort 1 Dose Level 3 | Cohort 2 Dose Level 1 | Cohort 2 Dose Level 2 | Cohort 2 Dose Level 3 | Cohort 3 Dose Level 1 | Cohort 3 Dose Level 2 | Cohort 4 Dose Level 1 |
|---|---|---|---|---|---|---|---|---|---|
| HypertensionVascular disorders | 9/13 | 9/12 | 5/7 | 9/14 | 14/14 | 9/9 | 8/13 | 7/7 | 5/7 |
| FatigueGeneral disorders | 10/13 | 9/12 | 5/7 | 13/14 | 11/14 | 7/9 | 9/13 | 4/7 | 4/7 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 12/13 | 6/12 | 4/7 | 8/14 | 7/14 | 5/9 | 7/13 | 3/7 | 3/7 |
| AnxietyPsychiatric disorders | 4/13 | 6/12 | 5/7 | 9/14 | 5/14 | 5/9 | 8/13 | 6/7 | 2/7 |
| HeadacheNervous system disorders | 7/13 | 8/12 | 6/7 | 8/14 | 8/14 | 5/9 | 7/13 | 3/7 | 3/7 |
| NauseaGastrointestinal disorders | 6/13 | 10/12 | 3/7 | 9/14 | 11/14 | 5/9 | 4/13 | 1/7 | 3/7 |
| DizzinessNervous system disorders | 6/13 | 6/12 | 3/7 | 9/14 | 8/14 | 3/9 | 10/13 | 4/7 | 2/7 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/13 | 9/12 | 2/7 | 3/14 | 8/14 | 4/9 | 1/13 | 1/7 | 4/7 |
| AnemiaBlood and lymphatic system disorders | 4/13 | 2/12 | 5/7 | 5/14 | 1/14 | 5/9 | 1/13 | 2/7 | 1/7 |
| ConstipationGastrointestinal disorders | 7/13 | 7/12 | 4/7 | 10/14 | 9/14 | 4/9 | 6/13 | 2/7 | 2/7 |
Patients within each cohort and dose level that completed treatment.
| Age, Categorical(Participants) | Cohort 1 Dose Level 1 | Cohort 1 Dose Level 2 | Cohort 1 Dose Level 3 | Cohort 2 Dose Level 1 | Cohort 2 Dose Level 2 | Cohort 2 Dose Level 3 | Cohort 3 Dose Level 1 | Cohort 3 Dose Level 2 | Cohort 4 Dose Level 1 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 8 | 3 | 12 | 9 | 6 | 6 | 3 | 6 | 63 |
| >=65 years | 3 | 4 | 4 | 2 | 5 | 3 | 7 | 4 | 1 | 33 |
| Age, Continuous(years) | Cohort 1 Dose Level 1 | Cohort 1 Dose Level 2 | Cohort 1 Dose Level 3 | Cohort 2 Dose Level 1 | Cohort 2 Dose Level 2 | Cohort 2 Dose Level 3 | Cohort 3 Dose Level 1 | Cohort 3 Dose Level 2 | Cohort 4 Dose Level 1 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 60.5 (44 to 75) | 59.8 (35 to 80) | 62.1 (32 to 80) | 57.9 (32 to 78) | 58.3 (36 to 75) | 58.6 (42 to 73) | 67.3 (49 to 90) | 66.7 (59 to 75) | 59.4 (49 to 79) | 60.9 (32 to 90) |
| Sex: Female, Male(Participants) | Cohort 1 Dose Level 1 | Cohort 1 Dose Level 2 | Cohort 1 Dose Level 3 | Cohort 2 Dose Level 1 | Cohort 2 Dose Level 2 | Cohort 2 Dose Level 3 | Cohort 3 Dose Level 1 | Cohort 3 Dose Level 2 | Cohort 4 Dose Level 1 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 6 | 6 | 3 | 7 | 7 | 2 | 5 | 6 | 1 | 43 |
| Male | 7 | 6 | 4 | 7 | 7 | 7 | 8 | 1 | 6 | 53 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 Dose Level 1 | Cohort 1 Dose Level 2 | Cohort 1 Dose Level 3 | Cohort 2 Dose Level 1 | Cohort 2 Dose Level 2 | Cohort 2 Dose Level 3 | Cohort 3 Dose Level 1 | Cohort 3 Dose Level 2 | Cohort 4 Dose Level 1 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 3 | 0 | 2 | 3 | 0 | 1 | 0 | 11 |
| Not Hispanic or Latino | 13 | 10 | 4 | 14 | 12 | 6 | 13 | 6 | 6 | 84 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Cohort 1 Dose Level 1 | Cohort 1 Dose Level 2 | Cohort 1 Dose Level 3 | Cohort 2 Dose Level 1 | Cohort 2 Dose Level 2 | Cohort 2 Dose Level 3 | Cohort 3 Dose Level 1 | Cohort 3 Dose Level 2 | Cohort 4 Dose Level 1 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 | 3 | 2 | 1 | 0 | 3 | 3 | 16 |
| White | 12 | 9 | 5 | 11 | 11 | 8 | 13 | 4 | 4 | 77 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Region of Enrollment(participants) | Cohort 1 Dose Level 1 | Cohort 1 Dose Level 2 | Cohort 1 Dose Level 3 | Cohort 2 Dose Level 1 | Cohort 2 Dose Level 2 | Cohort 2 Dose Level 3 | Cohort 3 Dose Level 1 | Cohort 3 Dose Level 2 | Cohort 4 Dose Level 1 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | 13 | 12 | 7 | 14 | 14 | 9 | 13 | 7 | 7 | 96 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2015 to primary completion in Mar 2025, 111 months.
Results were first posted in Oct 2026, 1 year 6 months after primary completion.
Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's 111 months is above that.
Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Texas Southwestern Medical Center →